
Human Longevity
Founded Year
2013Stage
Debt | AliveTotal Raised
$336.92MValuation
$0000Last Raised
$6.92M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+10 points in the past 30 days
About Human Longevity
Human Longevity is building a comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging-related disease and human biological decline. The company is developing and applying large-scale computing and machine learning to make discoveries from this data to generate personalized health insights. Its goal is to extend healthy human life by impacting human health and transforming the practice of medicine. Human Longevity was founded in 2013 and is based in San Diego, California.
ESPs containing Human Longevity
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The D2C genetic tests market refers to the direct-to-consumer genetic testing category, where individuals can purchase genetic tests without a healthcare provider's involvement. The market promises to provide personalized insights into an individual's genetic makeup, health risks, ancestry, and inherited traits. However, there are concerns about the accuracy and interpretation of results, as well …
Human Longevity named as Outperformer among 6 other companies, including Color, Helix, and Ancestry.
Research containing Human Longevity
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Human Longevity in 2 CB Insights research briefs, most recently on Aug 9, 2023.
Expert Collections containing Human Longevity
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Human Longevity is included in 2 Expert Collections, including Insurtech.
Insurtech
69 items
60+ underwriting data companies addressing 7 technology priorities, from wearables to genomic screening tools, that life insurance companies face.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Human Longevity Patents
Human Longevity has filed 15 patents.
The 3 most popular patent topics include:
- Bioinformatics
- Genetics
- Molecular biology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/5/2017 | 4/21/2020 | Health informatics, Biological databases, Medical diagnosis, Molecular biology, Biotechnology | Grant |
Application Date | 4/5/2017 |
---|---|
Grant Date | 4/21/2020 |
Title | |
Related Topics | Health informatics, Biological databases, Medical diagnosis, Molecular biology, Biotechnology |
Status | Grant |
Latest Human Longevity News
Aug 18, 2023
Share FOXO Technologies , a leader in the field of commercializing epigenetic biomarker technology , has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic biomarkers. “This partnership has been transformative for our research. DataRobot’s library of advanced algorithms and extensive automation capabilities have empowered us to rapidly transform DNA methylation data into useful insights, enabling us to develop and deploy software products quickly.” Epigenetic biomarkers provide valuable insights into the relationships among health, aging, and human longevity. These biomarkers are developed by leveraging DNA methylation microarray technology, which covers over 860,000 sites on the human genome. By automating the training and evaluation of thousands of models, FOXO is spearheading the commercialization of these revolutionary epigenetic biomarkers, paving the way for advancements in personalized wellness and disease prevention. FOXO’s partnership with DataRobot has proven instrumental in its efforts to propel this research forward. By leveraging DataRobot’s powerful AI platform, FOXO can efficiently analyze vast amounts of complex data, significantly expediting the identification of key biomarkers. FOXO believes the integration of AI and machine learning will enable FOXO to remain at the forefront of epigenetic research, ensuring unparalleled speed and computational capacity for their clients. Nichole Rigby, Director of Bioinformatics and Data Science at FOXO Technologies, emphasized the significance of their collaboration with DataRobot: “This partnership has been transformative for our research. DataRobot’s library of advanced algorithms and extensive automation capabilities have empowered us to rapidly transform DNA methylation data into useful insights, enabling us to develop and deploy software products quickly.” “We believe that with the ability to analyze data at scale, FOXO can uncover critical patterns and associations that hold the potential to reshape healthcare and wellness strategies,” stated CEO of FOXO Technologies, Tyler Danielson . “Our mission is to enhance human health and longevity through innovative technologies. Collaborating with DataRobot has given us the tools to accelerate our efforts, providing crucial insights into the aging process and ultimately enabling us to improve the quality of life for people worldwide.” FOXO Technologies is a pioneering biotechnology company at the forefront of commercializing epigenetic biomarker technology. Their mission is to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity outcomes for individuals and organizations alike. DataRobot is the leader in Value-Driven AI, a unique and collaborative approach to generative and predictive AI that combines an open platform, deep expertise and broad use-case experience to improve how organizations run, grow and optimize their business. The DataRobot AI Platform is the only complete AI lifecycle platform that interoperates with an organization’s existing investments in data, applications and business processes, and can be deployed on any cloud environment. Global organizations, including 40% of the Fortune 50, rely on DataRobot to drive greater impact and value from AI. Learn more at datarobot.com and follow us on LinkedIn and X (@DataRobot).
Human Longevity Frequently Asked Questions (FAQ)
When was Human Longevity founded?
Human Longevity was founded in 2013.
Where is Human Longevity's headquarters?
Human Longevity's headquarters is located at 4570 Executive Drive, San Diego.
What is Human Longevity's latest funding round?
Human Longevity's latest funding round is Debt.
How much did Human Longevity raise?
Human Longevity raised a total of $336.92M.
Who are the investors of Human Longevity?
Investors of Human Longevity include Freedom Acquisition I, Emerging Technology Partners, Threshold Ventures, Amino Capital, Celgene and 5 more.
Who are Human Longevity's competitors?
Competitors of Human Longevity include P4 Medical Laboratory and 4 more.
Compare Human Longevity to Competitors

Helix connects people with the most fundamental aspect of what makes them unique: their own DNA. The company empowers consumers to discover and explore their own genomes through insights provided by its ecosystem of content partners.

Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.

Transcarent operates as a consumer digital health company. It uses a combination of software, technology, and data science to supply consumers with information and access and provide better outcomes and cost-effective decisions. It provides telehealth services, at-home visits, appointment bookings, therapy, specialists, and pharmacy services. It serves consumers, employers and consultants, and providers and health systems. It was founded in 2020 and is based in Denver, Colorado.

LetsGetChecked offers at-home tests for a variety of conditions. The company builds and delivers at-home testing kits, including hormone tests, fertility tests, HPV tests and wellness tests for cholesterol or diabetes. Its services includes manufacturing, logistics, lab analysis, clinician support, and prescription fulfillment. The company was founded in 2015 and is based in Dublin, Ireland.

Optum (NYSE: UNH) is an information and technology-enabled health services business. The company delivers integrated solutions that help to modernize the health system and improve overall population health. Through Optum Care, the company offers a network of doctors nationwide. Optum Financial provides financing and payment services, expanding access to care in the health system. Additional offerings include Optum Rx, Optum Perks, Optum Bank, as well as a number of sites for health care professionals. The company was founded in 2011 and is based in Eden Prairie, Minnesota.

Geneticure tackles the standard of care for chronic and dangerous diseases by providing tools for clinicians to personalize therapy based on the specific patient. It uses pharmacogenomics to develop tests that clinicians use to help patients get better faster, and with less cost. Its post-diagnostic genetic tests ensure each patient receives only the fewest, most effective medications for their unique genetics and save unnecessary medications, visits, and adverse events. The company was founded in 2014 and is based in Rochester, Minnesota.